Centaur Clinical (CC) is a CRO created in 2016 that conducts pre-clinical assays and clinical studies in Europe directly or... View Article
Author Archives for Adeline Chauvigné
New member | Centaur Clinical
6 May 2024Centaur Clinical (CC) is a CRO created in 2016 that conducts pre-clinical assays and clinical studies in Europe directly or... View Article
OSE Immunotherapeutics and ARCAGY-GINECO Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer
Clinical trial sponsored and conducted by the French oncology cooperative group ARCAGY-GINECO and supported by Merck Sharp & Dohme Corp.... View Article
OSE Immunotherapeutics and ARCAGY-GINECO Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer
6 May 2024Clinical trial sponsored and conducted by the French oncology cooperative group ARCAGY-GINECO and supported by Merck Sharp & Dohme Corp.... View Article
Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome
Servier, an independent global pharmaceutical group, and OSE Immunotherapeutics, a French biotech, have announced enrollment of the first patient... View Article
Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome
6 May 2024Servier, an independent global pharmaceutical group, and OSE Immunotherapeutics, a French biotech, have announced enrollment of the first patient... View Article
New member | BioMAdvanced Diagnostics
BioMAdvanced Diagnostics aims to become a major player in biomarkers diagnostics, in France and internationally, starting with tests of immune... View Article
New member | BioMAdvanced Diagnostics
6 May 2024BioMAdvanced Diagnostics aims to become a major player in biomarkers diagnostics, in France and internationally, starting with tests of immune... View Article
Valneva commences rolling submission to MHRA for its inactivated, adjuvanted COVID-19 vaccine
Valneva, a specialty vaccine company focused on prophylactic vaccines for infectious diseases, today commenced rolling submission, for initial approval of... View Article
Valneva commences rolling submission to MHRA for its inactivated, adjuvanted COVID-19 vaccine
6 May 2024Valneva, a specialty vaccine company focused on prophylactic vaccines for infectious diseases, today commenced rolling submission, for initial approval of... View Article
Valneva and Pfizer complete recruitment for Phase 2 Trial of Lyme disease vaccine candidate
Valneva, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet... View Article
Valneva and Pfizer complete recruitment for Phase 2 Trial of Lyme disease vaccine candidate
6 May 2024Valneva, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet... View Article
OSE Immunotherapeutics announces voluntary pause of enrollment in the CoVepiT Phase 1 study
OSE Immunotherapeutics today announced a voluntary and temporary pause of enrollment and dosing in its ongoing Phase 1 clinical trial... View Article
OSE Immunotherapeutics announces voluntary pause of enrollment in the CoVepiT Phase 1 study
6 May 2024OSE Immunotherapeutics today announced a voluntary and temporary pause of enrollment and dosing in its ongoing Phase 1 clinical trial... View Article
OSE Immunotherapeutics Receives a €10 Million Payment Corresponding to the First Tranche of the Financing Granted by the European Investment Bank
This financing will further support the progress and expansion of OSE Immunotherapeutics’ lead clinical development programs in therapeutic areas with... View Article
OSE Immunotherapeutics Receives a €10 Million Payment Corresponding to the First Tranche of the Financing Granted by the European Investment Bank
6 May 2024This financing will further support the progress and expansion of OSE Immunotherapeutics’ lead clinical development programs in therapeutic areas with... View Article
Interview with Olivier Boisteau – Vice-President of Clean Biologics and of Atlanpole Biotherapies.
Leader of a group of over 200 people at Clean Biologics, a company offering a range of high-tech services to... View Article
Interview with Olivier Boisteau – Vice-President of Clean Biologics and of Atlanpole Biotherapies.
6 May 2024Leader of a group of over 200 people at Clean Biologics, a company offering a range of high-tech services to... View Article
Mérieux NutriSciences sells the European activities of Biofortis to its managing director who will continue its development alongside Institut Mérieux
Mérieux NutriSciences sells the European activities of Biofortis to its managing director who will continue its development alongside Institut Mérieux... View Article
Mérieux NutriSciences sells the European activities of Biofortis to its managing director who will continue its development alongside Institut Mérieux
6 May 2024Mérieux NutriSciences sells the European activities of Biofortis to its managing director who will continue its development alongside Institut Mérieux... View Article